Anthropic and OpenEvidence bring free clinical AI to doctors in ~100 low- and middle-income countries; OpenEvidence raises $250M at $15B
On Sept 22–23, 2026 (Reuters) Anthropic and OpenEvidence announced a collaboration to offer OpenEvidence's evidence-grounded clinical question answering free to physicians in about 100 low- and middle-income countries, starting with places such as Uganda, Angola, Sudan, Haiti and Mongolia, with Anthropic providing Claude capacity, engineers and funding. Days later (Sept 25) OpenEvidence was reported to have raised $250M at a $15B valuation and to be moving into oncology drug development.
Key facts
- Partnership: OpenEvidence adapts a free version to local disease patterns, diagnostics and treatments (usable by smartphone); Anthropic provides back-end model capacity, Claude credits, dedicated engineers and funding for an LMIC access team (Reuters, Fierce Healthcare)
- Extends earlier pilots in Rwanda and Botswana; a parallel Penn Medicine collaboration runs through the Botswana-UPenn Partnership (Fierce Healthcare)
- OpenEvidence is already free for clinicians in the US and Europe; US clinicians logged 42 million consultations in August 2026 (Reuters)
- Daniela Amodei (Anthropic president) said market incentives alone would not make this work without philanthropic support; Daniel Nadler: 'Access to medical knowledge shouldn't depend on geography'
- Funding (Axios Pro, Becker's, Sept 25): $250M at a $15B valuation, led by a16z and Byers Capital; up from $12B in January 2026 after a $250M Series D; a $20B valuation had been floated in July
- Nadler told Forbes OpenEvidence will develop oncology therapies, with a first drug in clinical trials before end-2026 (company claim)
What happened
OpenEvidence, the physician question-answering service used regularly by more than half of US doctors (Becker's), partnered with Anthropic to extend free access to lower-resourced health systems in Africa and Asia. In the same week its valuation rose to $15B and it disclosed plans to develop its own cancer drugs.
Why it matters
It is one of the largest deployments of a frontier model for clinical decision support in low-income countries, and a sign that medical AI companies are expanding from search into drug development.
Changelog
- 2026-09-30: created (resolves the leads.md line on OpenEvidence and the Anthropic partnership)
Sources (7)
- pressReuters via Business Standard: Anthropic, OpenEvidence collaborate to bring medical AI worldwide
- pressReuters via Express Tribune: Anthropic, OpenEvidence partner to bring medical AI worldwide
- pressFierce Healthcare: OpenEvidence partners with Anthropic, Penn Medicine to expand physician access to AI across Africa and Asia
- pressTNW: Anthropic and OpenEvidence to offer free medical AI to doctors in about 100 countries
- pressAxios Pro: OpenEvidence reportedly raises $250M at $15B valuation
- pressBecker's: OpenEvidence raises $250M at $15B valuation
- pressRefresh Miami: OpenEvidence hits $15B valuation as its ambitions move beyond medical search
id: 2026-09-22-anthropic-openevidence-lmic-physicians · updated 2026-09-30 · open in the interactive timeline